Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 237

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 237
---
 order to establish and validate its ability to manufacture supply of the Company’s Stendra® product. Any commercial sale of product manufactured during the performance of the Agreement must be subject to a subsequent commercial manufacturing services agreement (with associated quality agreement) between the parties before it can be offered for commercial sale.

15) Commitments and Contingencies Legal Proceedings On July 14, 2020, Greg Ford, the Chief Executive Officer of the Company, was terminated. On July 14, 2020, Mr. Ford, through his attorney, claimed that he was entitled to severance pay pursuant to an employment agreement following the termination of his employment on that same date. This claim is currently at an early stage where the Company is unable to determine the likelihood of any unfavorable outcome. From time to time, we are involved in various legal matters arising in the normal course of business. We do not expect the outcome of such proceedings, either individually or in the aggregate, to have a material effect on our financial position, cash flows or results of operations.

<div align='center'>F-24</div>

16) Income Taxes

The current and deferred income tax expense (benefit) for the years ended December 31, 2023, and 2022 is as follows:

| ​                                  | ​ |                                ​ | ​ | ​ |    ​ | ​ |
| ​                                  |   | For the Years Ended December 31, |   |   |      |   |
| ​                                  | ​ |                             2023 |   |   | 2022 |   |
| Current expense (benefit):         |   |                                ​ |   |   |    ​ |   |
| Federal                            | ​ |                                $ | — | ​ |    $ | — |
| State                              | ​ |                                  | — | ​ |      | — |
| Total current expense (benefit)    | ​ |                                  | — | ​ |      | — |
| Deferred expense (benefit):        | ​ |                                  |   | ​ |      |   |
| Federal                            | ​ |                                  | — | ​ |      | — |
| State                              | ​ |                                  | — | ​ |      | — |
| Total deferred expense (benefit)   | ​ |                                  | — | ​ |      | — |
| Total income tax expense (benefit) | ​ |                                $ | — | ​ |    $ | — |

A reconciliation of the Company’s statutory income tax rate to the Company’s effective